Modulation of immune effector cells activation with specific focus on T cells and B cells - Biowebspin | Biowebspin
Logo Biowebspin


The worldwide platform to find industrial partners and funding

External open innovation partner programModulation of immune effector cells activation with specific focus on T cells and B cells

Are you working on pathophysiological T-cell functions and/or B-cells?
Have you identified novel compounds modulating these cells activation?
Are you interested in partnering with a pharma company to translate your new science into a new medicine?
What we are looking for

We are looking for any type of New Molecular Entity (small molecules, biologics, peptides) involved in the modulation of immune effector cells activation with specific focus on T-cells and B-cells.

Secondly, we are also looking for novel compounds in:

  • Immune-inflammatory and autoimmune diseases preferably on Lupus, primary Sjögren’s syndrome, and systemic sclerosis
  • Interest in other indications in this field, especially involving an unmet therapeutic need and/or similar physiopathological mechanism
  • Targeted molecules whose therapeutic approach is supported by biomarkers and/or a mode of action

At discovery stage, projects must be supported by clear scientific data deriving from in vitro assays and in vivo animal models (compulsory). Selection will prioritize preclinical candidate. We are not interested in marketed drugs (drug repositioning).

What we offer and how does it work

All proposals will be assessed by our Research & Development team. Based on the level of interest within the Company research portfolio and strategic fit, we will enter into discussion with selected candidate(s), potentially leading to partnership agreements or collaborations.

Proponents that submit proposals of interest will be contacted within 8 weeks of submission to clarify additional details.

What to submit

Submit a proposal in a form which is available online (it takes about 15 minutes).The proposal should be brief, sufficient to provide the main body of the proposal and its innovativeness. The applicant should also provide information about his or her critical knowledge that is applicable for the project, and how the knowledge could be supplemented (i.e., what is additionally required to complete the project). The applicants are strongly encouraged to give us additional information including references or other materials to facilitate the evaluation process.

Privacy, confidentiality & FAQ

While Servier will not share the information beyond its own staff, your initial proposal should contain only non-confidential information.

If your proposal is selected, you will be requested to complete a Confidentiality Disclosure Agreement (CDA).


Biowebspin pays a lot of attention to the privacy, intellectual property, confidentiality and security of its member data.

Biowebspin is a matchmaking platform between academia & industry. Biowebspin is not involved in the IP discussion and is not charging any success or license fees. Your «Open Innovation» opportunities on Biowebspin are only visible by industrials and the Biowebspin team. You can remove your data at any time. Biowebspin strongly recommends that you do not enter any confidential data or if you do so, that your technology transfer office agrees the submission of your pre-proposal on Biowebspin. If you directly submit your pre-proposal on an industrial partner website, you will agree their terms, conditions and privacy policy of our industrial partner website. Biowebspin is not responsible for the content, accuracy, or opinion of its industrial partner website. As a Swiss International company, Biowebspin has high standard security and privacy system. Biowebspin is in accordance with the Federal Data Protection and Information Commissioner. Contact us for more information about the terms and conditions of the matchmaking service of Biowebspin.


Servier is a leading pharmaceutical company headquartered in France. Committed to improving health worldwide, corporate growth is driven by Servier’s constant search for innovation in five areas of excellence: cardiology, metabolism, neuropsychiatry, oncology and rheumatology

Privately own company, Servier reinvests 25% of its turnover (€3.9 billion in 2015) in Research and development and all its profits in its growth

About Biowebspin:

Biowebspin is the #1 academia-industry partnering network in Life Sciences.
For academics, Biowebspin is the platform to find industrial partners and funding for their research projects matching R&D programs of more than 500 leading Life Sciences companies and foundations.

Check if one program will fit your researches for industrial collaboration and funding